BRAF and neoplasm: BRAF mutation was reported to exist in 35–70% of PTCs, and one mutation called BRAF V600E has been shown to correlate with aggressive characteristics of PTC, including ETE, advanced tumor stage at presentation, CLNM and DM [19].